Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy.

Autor: van der Doelen MJ; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands. Maarten.vanderDoelen@radboudumc.nl.; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. Maarten.vanderDoelen@radboudumc.nl., Oving IM; Department of Medical Oncology, Ziekenhuisgroep Twente, Almelo, Netherlands., Wyndaele DNJ; Department of Nuclear Medicine, Catharina Hospital, Eindhoven, The Netherlands., van Basten JP; Department of Urology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands., Terheggen F; Department of Medical Oncology, Bravis Hospital, Roosendaal, The Netherlands., van de Luijtgaarden ACM; Department of Medical Oncology, Reinier de Graaf Gasthuis and Reinier Haga Prostate Cancer Center, Delft, The Netherlands., Oyen WJG; Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, The Netherlands.; Department of Biomedical Sciences, Humanitas University, Milan, Italy.; Department of Nuclear Medicine, Humanitas Clinical and Research Center, Milan, Italy., van Schelven WD; Department of Nuclear Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands., van den Berkmortel F; Department of Medical Oncology, Zuyderland Medical Center, Sittard, The Netherlands., Mehra N; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Janssen MJR; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands., Prins JB; Department of Medical Psychology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands., Gerritsen WR; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Custers JAE; Department of Medical Psychology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands., van Oort IM; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
Jazyk: angličtina
Zdroj: Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2023 Mar; Vol. 26 (1), pp. 142-150. Date of Electronic Publication: 2022 Jul 08.
DOI: 10.1038/s41391-022-00569-8
Abstrakt: Background: Radium-223 is a registered treatment option for symptomatic bone metastatic castration-resistant prostate cancer (mCRPC). Aim of this multicenter, prospective observational cohort study was to evaluate health-related quality of life (HR-QoL), psychological distress and fatigue in mCRPC patients treated with radium-223.
Methods: Primary endpoint was cancer-specific and bone metastases-related HR-QoL, as measured by the EORTC QLQ-C30 and BM-22 questionnaires. Secondary endpoints were psychological distress and fatigue, evaluated by the HADS and CIS-Fatigue questionnaires. Outcomes were analyzed for the total cohort and between subgroups (1-3 versus 4-5 versus 6 radium-223 injections). A trajectory analysis was performed to explore HR-QoL patterns over time.
Results: In total, 122 patients were included for analysis. Baseline HR-QoL, pain intensity, psychological distress and fatigue were worse in patients who did not complete radium-223 therapy. In patients who completed therapy, stabilization of HR-QoL was perceived and psychological distress and fatigue remained stable, whereas clinically meaningful and statistically significant deterioration of HR-QoL, psychological distress and fatigue over time was observed in patients who discontinued radium-223 therapy. Trajectory analysis revealed that HR-QoL deterioration over time was more likely in patients with baseline opioid use, low hemoglobin and high alkaline phosphatase levels.
Conclusions: Patients who discontinued radium-223 therapy showed worse HR-QoL, psychological distress and fatigue at baseline and more frequent deterioration of HR-QoL, psychological distress and fatigue over time when compared to patients who completed therapy. Specific attention with regard to HR-QoL during follow-up is indicated in patients with opioid use, low hemoglobin and high alkaline phosphatase levels before radium-223 therapy initiation.
Clinical Trial Registration Number: NCT04995614.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: